NOVEL HETEROCYCLIC SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING INHIBITORY ACTION ON CANCER CELL GROWTH, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Russian patent published in 2025 - IPC C07D403/12 C07D487/10 C07D491/107 A61K31/506 A61K31/5377 A61K31/541 A61P35/00 

FIELD: chemistry.

SUBSTANCE: present invention relates to a novel compound of chemical formula 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing it. In chemical formula 1, the values of radicals are as follows: X is an oxygen atom, R₁ is a C1-C4 alkyl group, R₂ is H or C1-C4 alkyl group, R₃ is a hydrogen atom, R₄ is a hydrogen atom or a halogen atom, R₅ is a hydrogen atom, R₆ is a C1-C4 alkyl group, R₇ is a pyrazolyl group substituted or unsubstituted with a C1-C4 alkyl group, an imidazole group substituted or unsubstituted with a C1-C4 alkyl group, or a triazolyl group substituted or unsubstituted with a C1-C4 alkyl group, and R₈ is an aliphatic heterocyclic group substituted or unsubstituted with a C1-C4 alkyl group and containing one or more heteroatoms selected from nitrogen atoms, oxygen atoms and sulphur atoms, and from 2 to 10 carbon atoms; or N¹,N¹,N²-tri(C1-C4 alkyl)ethylenediamine group, where X forms a double bond with S, and S forms a single bond with N. Chemical formula 1.

EFFECT: pyrimidine derivative presented by chemical formula 1 effectively inhibits the growth of cancer cells with ALK mutation and EGFR mutation, due to which it can be effectively used in treating lung cancer.

7 cl, 2 tbl, 12 ex